Skip to Main Content

Author Details

Himisha Beltran
Dana-Farber Cancer Institute
2010
200
68
PMIDPaper TitleJournal TitlePublished Year
37676819Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.J Natl Cancer Inst2024
37676819Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.J Natl Cancer Inst2024
35999168Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice.Eur Urol Focus2023
35999168Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice.Eur Urol Focus2023
37919447Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.NPJ Precis Oncol2023
37967200Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.Sci Transl Med2023
37704749Evolution of structural rearrangements in prostate cancer intracranial metastases.NPJ Precis Oncol2023
38049603Metabolically regulated lineages in prostate cancer.Nat Cell Biol2023
37347559Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.J Clin Invest2023
37470668The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity.Cancer Discov2023
37330052Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.Ann Oncol2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
36996380Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).J Clin Oncol2023
37052520Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers.Mol Cancer Res2023
37038004Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.Nat Cancer2023
37546702The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.Cancer Res Commun2023
37223924Immunogenomic Landscape of Neuroendocrine Prostate Cancer.Clin Cancer Res2023
37967200Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.Sci Transl Med2023
37919447Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.NPJ Precis Oncol2023
37704749Evolution of structural rearrangements in prostate cancer intracranial metastases.NPJ Precis Oncol2023
37546702The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.Cancer Res Commun2023
38049603Metabolically regulated lineages in prostate cancer.Nat Cell Biol2023
37052520Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers.Mol Cancer Res2023
37347559Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.J Clin Invest2023
37470668The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity.Cancer Discov2023
37038004Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.Nat Cancer2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
37330052Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.Ann Oncol2023
36996380Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).J Clin Oncol2023
37223924Immunogenomic Landscape of Neuroendocrine Prostate Cancer.Clin Cancer Res2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
34045389Germline <i>BRCA2</i> mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy.Asian J Androl2022
35771632CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.Cancer Res2022
35657153Future directions for precision oncology in prostate cancer.Prostate2022
35450732Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.Eur Urol2022
35579578Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.Clin Adv Hematol Oncol2022
35579577Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.Clin Adv Hematol Oncol2022
35440417Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].Eur Urol2022
36344556The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer.Sci Rep2022
35552307Editorial: Metastatic prostate cancer: a wealth of data to put into practice.Curr Opin Urol2022
35617398Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.Science2022
35983951DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.Oncologist2022
36317634A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.J Clin Invest2022
36542647Impact of early detection on cancer curability: A modified Delphi panel study.PLoS One2022
36455195Response to MEK Inhibitor Therapy in <i>MAP2K1</i> (<i>MEK1</i>) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of <i>MAP2K1</i> Mutations in Non-Small-Cell Lung Cancer.JCO Precis Oncol2022
34045389Germline <i>BRCA2</i> mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy.Asian J Androl2022
34990290Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer.J Clin Oncol2022
35064078Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.Proc Natl Acad Sci U S A2022
34742584Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology.Eur Urol2022
  • 1 - 50 of 400

Recommended Authors

Yang Liu
Veracyte inc.
Career Start Year 2019
Number of shared co-authors 70
Vincent Huang
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 34
George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2016
Number of shared co-authors 29
Richard J Rebello
University of Melbourne
Career Start Year 2015
Number of shared co-authors 8
Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 10
Alexandra Corella
Fred Hutchinson Cancer Research Center
Career Start Year 2015
Number of shared co-authors 10
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 23
Simpa S Salami
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 46
Steven Hazell
Royal Marsden NHS Foundation Trust
Career Start Year 2011
Number of shared co-authors 10
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 45
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 16
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 40
Shancheng Ren
Shanghai Changzheng Hospital
Career Start Year 2007
Number of shared co-authors 38
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 20
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 13
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 17
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 27
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 18
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 80
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 24
David T Miyamoto
Massachusetts General Hospital
Career Start Year 2000
Number of shared co-authors 13
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 14
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 12
Renea A Taylor
Peter MacCallum Cancer Centre
Career Start Year 1999
Number of shared co-authors 18
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 51
Phuoc T Tran
University of Maryland School of Medicine
Career Start Year 1996
Number of shared co-authors 78
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 39
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 73
Isla P Garraway
David Geffen School of Medicine University of California Los Angeles
Career Start Year 1993
Number of shared co-authors 59
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 20

Collaborators

Mark A Rubin
University of Bern
Co-authored papers 75
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 56
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 49
Olivier Elemento
Meyer Cancer Center
Co-authored papers 41
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 37
Francesca Demichelis
University of Trento
Co-authored papers 35
Martin E Gleave
University of British Columbia
Co-authored papers 30
David M Nanus
Sandra and Edward Meyer Cancer Center
Co-authored papers 30
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Co-authored papers 25
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 25
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 22
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 21
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 21
Rohan Bareja
Case Western Reserve University
Co-authored papers 19
Loredana Puca
Sandra and Edward Meyer Cancer Center
Co-authored papers 18
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 18
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 18
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 17
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 16
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 16
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 16
Cora N Sternberg
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 16
Yuzhuo Wang
University of British Columbia
Co-authored papers 15
Amina Zoubeidi
University of British Columbia
Co-authored papers 15
Eric J Small
University of California san francisco
Co-authored papers 15
David S Rickman
Meyer Cancer Center
Co-authored papers 15
Davide Prandi
University of Trento
Co-authored papers 15
Maha Hussain
Northwestern University
Co-authored papers 14
Kenneth Eng
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 13
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Release 1.2